Joel Richard

Dr. Joel Richard

MedinCell

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2022 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
AGAndrea Gonella
Andrea Gonella
SGSylvestre Grizot
Sylvestre Grizot
FLFang Liu
Fang Liu
ANAdolfo López Noriega
Adolfo López Noriega
JRJoel Richard
Joel Richard
The development of long-acting injectables (LAIs) for protein and peptide therapeutics has been a key challenge over the last 20 years. If these molecules offer advantages due to their high specifi...

Verified
Journal Article
Open access
PDF file
CPCharlotte Peloso
Charlotte Peloso
ATAnne-Pascale Trichet
Anne-Pascale Trichet
JDJacques Descotes
Jacques Descotes
JRJoel Richard
Joel Richard
CRChristophe Roberge
Christophe Roberge
ALAdolfo Lopez-Noriega
Adolfo Lopez-Noriega
The present study aims to investigate the loco-regional tolerability and injection parameters (i.e., flow rate and administration volume) of an in situ forming depot (ISFD) in Göttingen minipigs, to secure both the therapeutic procedure and compliance in chronic medical prescriptions. The ISFD BEPO® technology (MedinCell S.A.) is investigated over 10 days, after a single subcutaneous injection of test item based on a DMSO solution of diblock and triblock polyethylene glycol-polylactic acid copolymers. Injection sites are systematically observed for macroscopic loco-regional skin reactions as well as ultrasound scanning, enabling longitudinal in vivo imaging of the depot. Observations are complemented by histopathological examinations at 72 h and 240 h post-injection. Overall, no treatment-emergent adverse effects are macroscopically or microscopically observed at the subcutaneous injection sites, for the tested injection flow rates of 1 and 8 mL/min and volumes of 0.2 and 1 mL. The histopathology examination confirms an expected foreign body reaction, with an intensity depending on the injected volume. The depot morphology is similar irrespective of the administration flow rates. These results indicate that the ISFD BEPO® technology can be considered safe when administered subcutaneously in Göttingen minipigs, a human-relevant animal model for subcutaneous administrations, in the tested ranges.